NVAX Starts Late-Stage Study on COVID-19-Flu Combo & Flu Vaccines [Yahoo! Finance]
Novavax, Inc. (NVAX)
Last novavax, inc. earnings: 3/11 04:17 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.novavax.com/investor-relations
Company Research
Source: Yahoo! Finance
The study will compare the immunogenicity and safety of the CIC vaccine with separate administrations of Novavax's currently authorized COVID-19 vaccine and a licensed seasonal influenza vaccine. Management will also assess the immunogenicity and safety of its standalone influenza vaccine. Both experimental vaccines will utilize the company's proprietary adjuvant technology, Matrix-M, to enhance the immune response. The study will focus on adults aged 65 and older. Novavax is in active discussions with the FDA for accelerated approval for both vaccines. Though more clarity on these discussions is expected in the second quarter of 2025, management has decided to enroll nearly 2,000 study participants in an initial cohort of the study. NVAX is also exploring strategic collaborations to finance the late-stage development and potential commercialization of both candidates. This initiation is supported by data from a mid-stage study, which showed that both vaccines were well-toler
Show less
Read more
Impact Snapshot
Event Time:
NVAX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVAX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVAX alerts
High impacting Novavax, Inc. news events
Weekly update
A roundup of the hottest topics
NVAX
News
- Novavax Advances Corporate Growth Strategy Through Sanofi Partnership, Including Achievement of First $50 Million MilestonePR Newswire
- Why Is Novavax (NVAX) Up 13.6% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Institutional investors control 53% of Novavax, Inc. (NASDAQ:NVAX) and were rewarded last week after stock increased 6.3% [Yahoo! Finance]Yahoo! Finance
- FDA Grants Fast Track Tag to SNY's Two COVID & Flu Vaccine Candidates [Yahoo! Finance]Yahoo! Finance
- Novavax, Inc. (NASDAQ: NVAX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $19.00 price target on the stock.MarketBeat
NVAX
Earnings
- 11/12/24 - Beat
NVAX
Sec Filings
- 1/3/25 - Form 4
- 1/2/25 - Form 4
- 1/2/25 - Form 4
- NVAX's page on the SEC website